Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE ( © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 March 2020

Abstract and Keywords

Pediatric psychopharmacology is a relatively young field. Through the decade of the 1990s and into the early 2000s, there was an unprecedented increase in the number of new psychotropic drugs and new formulations of older drugs. During this period, there was also a series of well-intended federal policies that provided pressure and incentives for pharmaceutical companies to conduct studies of new medications in children. The National Institutes of Health also provided funding for investigator-initiated clinical trials. Although still less than optimal, we now have a body of data on stimulants, selective serotonin reuptake inhibitors, and atypical antipsychotics. These three psychotropic drug classes are the most commonly used in children and adolescents. This chapter charts the rise in use of these drug classes and presents their risks and benefits.

Keywords: stimulants, selective serotonin reuptake inhibitors, atypical antipsychotics, pediatric psychopharmacology, psychotropic drugs, federal drug policies

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.